Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 2 selected

Guidance programme

Showing 1 to 50 of 815

TitleReference numberPublishedLast updated
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA1007
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1006
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and overTA1002
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and overTA1003
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusionTA1004
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA1005
Iptacopan for treating paroxysmal nocturnal haemoglobinuriaTA1000
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatmentTA1001
Vibegron for treating symptoms of overactive bladder syndromeTA999
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinomaTA997
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Risankizumab for treating moderately to severely active ulcerative colitisTA998
Relugolix for treating hormone-sensitive prostate cancerTA995
Linzagolix for treating moderate to severe symptoms of uterine fibroidsTA996
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)TA994
Abaloparatide for treating osteoporosis after menopauseTA991
Burosumab for treating X-linked hypophosphataemia in adultsTA993
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapyTA992
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisTA988
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia BTA989
Tenecteplase for treating acute ischaemic strokeTA990
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA986
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)TA987
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinomaTA985
Selective internal radiation therapies for treating hepatocellular carcinomaTA688
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Voxelotor for treating haemolytic anaemia caused by sickle cell diseaseTA981
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Atogepant for preventing migraineTA973
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969

Results per page

  1. 10
  2. 25
  3. 50
  4. All